key: cord-0759688-mq0hq2js
authors: Pahima, Hadas; Zaffran, Ilan; Ben-Chetrit, Eli; Jarjoui, Amir; Gaur, Pratibha; Manca, Maria Laura; Reichmann, Dana; Orenbuch-Harroch, Efrat; Puxeddu, Ilaria; Zinner, Carl; Tzankov, Alexandar; Levi-Schaffer, Francesca
title: COVID-19 patients have increased levels of membrane-associated and soluble CD48
date: 2022-03-18
journal: bioRxiv
DOI: 10.1101/2022.03.18.484843
sha: 00f3e3f5ad45d64fbde295926abe2c21fe486e45
doc_id: 759688
cord_uid: mq0hq2js

COVID-19 is a respiratory-centered systemic disorder caused by SARS-CoV-2. The disease can progress into a severe form causing acute lung injury. CD48 is a co-signaling receptor, existing as both membrane-bound and soluble forms reported to be dysregulated in several inflammatory conditions. Therefore, we reasoned that CD48 could be deregulated in COVID-19 as well. Here we analyzed CD48 expression in autoptic sections and peripheral blood leukocytes and sera of COVID-19 patients by gene expression profiling (HTG® autoimmune panel), immunohistochemistry, flow cytometry and ELISA. Lung tissue of COVID-19 patients showed increased CD48 mRNA expression and infiltration of CD48+ lymphocytes. In the peripheral blood, mCD48 was considerably increased on all evaluated cells, and additionally, sCD48 levels were significantly higher in COVID-19 patients independently of disease severity. Considering the alterations of mCD48 and sCD48, a specific role for CD48 in COVID-19 can be assumed, suggesting it as a potential target for therapy.

healthy controls once patients recovered from the disease (5961 ± 376) ( Fig 3F,  Table 3 ). 128 cells was found also in healthy controls (r: 0.8629; p-value: 0.0005), while the other 152 correlations were detected only in the patients' cells (Fig 4F-H) . Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 550 0.0001 Table 3 : sCD48 levels in the sera of aged-matched active or recovered COVID-19 patients and healthy controls. Data presented as mean ± SEM

Monocyte/macrophage-elicited natural killer cell dysfunction in Ferritin D-dimer Creatinine CRP

 Appendix Table S2 ) during the first disease wave in Switzerland (March-May 2020)